---
company: Wave Life Sciences, Inc.
ticker: WVE
form: 8-K
filed: 2026-10-27
accepted: 2026-10-27T11:35:46+00:00
accession: 0001193125-26-432690
source: https://www.sec.gov/Archives/edgar/data/1631574/000119312526432690/
---

# Wave Life Sciences (WVE) Q3 2026 earnings

## Header

- Company: Wave Life Sciences, Inc.
- Reported: 2026-10-27 07:35 BMO ET
- Source: 8-K only — accession 0001193125-26-432690, Item 2.02 + Exhibit 99.1
- Verdict: Revenue increased 73% YoY to $13.2 million, but net loss widened to $0.30 per share from $0.32, driven by higher R&D and G&A expenses.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---:|---:|---|---|
| Revenue | $13.2M | +73% | — | Ex. 99.1, income statement |

## Revenue breakdown

not stated in the 8-K

## Margins and costs

- Gross margin: not stated in the 8-K
- Operating expenses: $79.2M (+24% YoY)
- One-offs in the quarter: not stated in the 8-K
- Effective tax rate: not stated in the 8-K
- Non-GAAP bridge: not stated in the 8-K

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---|---|---|
| Cash, cash equivalents, and marketable securities | $431.0M | — | — | — |
| Weighted-average common stock | 204.2M | — | — | — |

## Guidance

not stated in the 8-K

## What drove it

- Revenue story: Revenue increased 73% YoY to $13.2 million, driven by increased collaboration activities and milestone payments.
- EPS story: Net loss per share widened to $0.30 from $0.32, driven by higher operating expenses.
- One-off check: not stated in the 8-K

## The good

- Revenue increased 73% YoY to $13.2 million.
- Cash, cash equivalents, and marketable securities of $431.0 million as of September 30, 2026.
- Expected cash runway into 3Q 2028.

## The bad

- Net loss per share widened to $0.30 from $0.32.
- Operating expenses increased 24% YoY to $79.2 million.
- Cash and cash equivalents decreased 67% QoQ to $197.3 million.

## The ugly

- none

## Open questions

- The release does not provide a reconciliation of GAAP net loss to adjusted net loss or adjusted net loss per share.
- The release does not provide a reconciliation of GAAP operating expenses to adjusted operating expenses.

## Full release

### Earnings: WVE — filed 2026-10-27

Wave Life Sciences, Inc. (WVE) · Form 8-K, Item 2.02 · Filed 2026-10-27 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1631574/000119312526432690/)

Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update

Planning underway for registrational trial of

WVE-006

(RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers

Advancing

WVE-007

(INHBE siRNA) across treatment settings: dosing ongoing in Phase 2a monotherapy clinical trial in individuals with higher BMI and comorbidities, initiated Phase 2a combination trial, and remain on track to initiate post-incretin maintenance trial this quarter

CTA submission for

WVE-008 for PNPLA3 liver disease (RNA editing) on track for 4Q 2026

GSK selected a GalNAc-siRNA development candidate using Wave’s proprietary SpiNA design; three additional hepatic and extra-hepatic collaboration programs advancing towards potential candidate selection

Well capitalized with cash, cash equivalents, and marketable securities of $431.0 million as of September 30, 2026; additional $12 million milestone from GSK to be received in 4Q 2026; expected cash runway into 3Q 2028

Investor conference call and webcast at 8:30 a.m. ET today

CAMBRIDGE, Mass., October 27, 2026 – Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

“We continue to make notable progress advancing our lead clinical programs. Following positive FDA feedback, planning is underway for our potentially registrational trial of

WVE-006 for AATD, which we believe offers an efficient path to potential full and accelerated approval, without the need for a separate confirmatory trial. Our growing body of clinical data support

WVE-006’s potential to offer a new standard of care for individuals living with AATD,” said Paul Bolno, MD, MBA, President and Chief Executive Officer at Wave Life Sciences. “We also continue to make notable progress advancing

WVE-007 across treatment settings. Dosing is ongoing in our Phase 2a INLIGHT™ trial evaluating

WVE-007 as a monotherapy. As expected, we are pleased to report that to date baseline levels of adiposity in the Phase 2a portion of INLIGHT are substantially higher than in the Phase 1 portion and in line with

Phase 2 and 3 obesity trials. We believe this portion of the trial is well suited to demonstrate

WVE-007’s potential to deliver meaningful improvements in body composition and healthy weight loss. Our combination trial of

WVE-007 with weekly tirzepatide is underway, where we believe

WVE-007 can demonstrate enhanced fat loss and cardiometabolic benefit, without additional muscle loss. We also remain on track to initiate a post-incretin maintenance trial of

WVE-007 in the fourth quarter that has the potential to unlock an entirely new frontier in obesity by enabling patients an off-ramp for their incretin therapy.”

Dr. Bolno added, “Importantly, our PRISM platform and chemistry continue to demonstrate unique value both within our own pipeline and beyond. The advancement of a development candidate by GSK reflects the recognition of Wave’s differentiated technology, including our best-in-class siRNA with SpiNA design, with three additional collaboration programs still advancing. The appointment of Monika Vnuk, with her breadth of experience, in our newly-created role of Chief Business Officer, is meant to capitalize on and expand the potential of our platform and support the next phase of Wave’s growth. We look forward to sharing new data supporting our platform and capabilities at our upcoming Research Day next week, where we will be joined by a leading hepatologist who will discuss PNPLA3 I148M liver disease and opportunity for an RNA editing approach.”

Recent Business Highlights and Expected

Milestones

Obesity

Alpha-1 antitrypsin deficiency (AATD)

PNPLA3 I148M liver disease

Corporate Highlights

Financial Highlights

Investor Conference Call and Webcast

Wave will host an investor conference call today at 8:30 a.m. ET to review the third quarter 2026 financial results and pipeline updates. A webcast of the conference call can be accessed by visiting “Investor Events” on the investor relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here. Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About

Wave Life Sciences

Wave Life Sciences

(Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of

RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s lead pipeline programs include obesity

(WVE-007), alpha-1 antitrypsin deficiency

(WVE-006), and PNPLA3 I148M liver disease

(WVE-008), as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on

X and

LinkedIn.

Forward-Looking Statements

This press release contains... (d-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, concerning our goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following, among others: the anticipated initiation, timing, design, progress, data and announcements related to our clinical trials, including interactions with and feedback from regulators and any potential registrational submissions based on these data; the future performance and results of our programs in clinical trials, including the anticipated therapeutic benefits of such programs, and our expectations with respect to how our clinical data may predict success for our future therapeutic candidates and data readouts; the potential commercialization of our programs the potential size of the markets that our therapeutics may address; preclinical activities and programs, the anticipated therapeutic benefit based on such preclinical data, and their potential to transition into clinical-stage programs, and the timing, progress and announcement of such events; the progress and potential benefits, including the potential achievement of milestones, of collaborations and strategic partnerships; the expected benefits of our stereopure oligonucleotides compared with stereorandom alternatives; the breadth, versatility, and potential of our PRISM® drug discovery and development platform; the potential benefits of our

RNA-targeting modalities, including RNAi (SpiNA), and RNA editing (AIMers) compared with competing technologies; the potential for certain of our programs to be best-in-class or first-in-class, or to change the existing treatment paradigm or show substantial benefits over existing standards of care; our financial performance, including the anticipated duration of our cash runway and our ability to fund future operations; our intended uses of capital; and our expectations regarding the impact of any potential global macro events on our business. The words “may,”

“will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,”

“believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual results to differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the clinical results and timing of our programs, which may not support further development of our product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; our effectiveness in managing current and future clinical trials and regulatory processes; the continued development and acceptance of nucleic acid therapeutics as a class of drugs; our ability to demonstrate the therapeutic benefits of our stereopure candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our ability to obtain, maintain and protect intellectual property; our ability to fund our operations and to raise additional capital as needed; competition from others developing therapies for similar uses; and any impacts on our business as a result of or related to any global economic uncertainty or market disruptions, as well as the other risks and uncertainties described in the section entitled “Risk Factors” in our most recent Annual Report on Form

10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings we make with the SEC from time to time. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We undertake no obligation, except to the extent required by law, to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:

Kate Rausch

VP, Corporate Affairs and Investor Relations

+1

617-949-4827

Investors:

James

Salierno

Director, Investor Relations

+1

617-949-4043

InvestorRelations@wavelifesci.com

Media

:

Katie Sullivan

Senior Director, Corporate Communications

+1

617-949-2936

MediaRelations@wavelifesci.com

#### Financial statements

##### Income Statement (Three Months Ended September 30, — (In thousands, except share and per share amounts))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenue | 13,158 | 7,608 | 53,676 | 25,482 |
| Operating expenses: | Research and development | 53,843 | 45,874 | 152,576 | 129,965 |
| Operating expenses: | General and administrative | 25,362 | 18,087 | 72,246 | 54,433 |
| Operating expenses: | Total operating expenses | 79,205 | 63,961 | 224,822 | 184,398 |
| Operating expenses: | Loss from operations | -66,047 | -56,353 | -171,146 | -158,916 |
| Other income, net: | Interest income | 4,378 | 2,177 | 14,391 | 7,424 |
| Other income, net: | Other income (expense) | -243 | 324 | -599 | 293 |
| Other income, net: | Total other income, net | 4,135 | 2,501 | 13,792 | 7,717 |
| Other income, net: | Loss before income taxes | -61,912 | -53,852 | -157,354 | -151,199 |
| Other income, net: | Net loss | -61,912 | -53,852 | -157,354 | -151,199 |
| Other income, net: | Net loss per share—basic and diluted | -0.3 | -0.32 | -0.78 | -0.92 |
| Other income, net: | Weighted-average common stock used in computing net loss per share—basic and diluted | 204,222,255 | 167,739,208 | 202,814,464 | 164,773,525 |
| Other comprehensive loss: | Net loss | -61,912 | -53,852 | -157,354 | -151,199 |
| Other comprehensive loss: | Foreign currency translation gain (loss) | -125 | -29 | -6 | 72 |
| Other comprehensive loss: | Unrealized loss on marketable securities | -268 |  | -309 |  |
| Other comprehensive loss: | Comprehensive loss | -62,305 | -53,881 | -157,669 | -151,127 |

##### Balance Sheet (September 30, 2026 — (In thousands, except share amounts))

| | September 30, 2026 | December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 197,315 | 602,068 |
| Current assets: | Marketable securities | 233,434 |  |
| Current assets: | Accounts receivable | 12,000 | 1,276 |
| Current assets: | Prepaid expenses | 11,556 | 8,395 |
| Current assets: | Other current assets | 4,325 | 3,075 |
| Current assets: | Total current assets | 458,630 | 614,814 |
| Long-term assets: | Property and equipment, net of accumulated depreciation of $51,391 and $49,522 as of September 30, 2026 and December 31, 2025, respectively | 6,239 | 7,405 |
| Long-term assets: | Long-term marketable securities | 263 |  |
| Long-term assets: | Operating lease right-of-use assets | 38,088 | 12,458 |
| Long-term assets: | Restricted cash | 3,815 | 3,806 |
| Long-term assets: | Other assets | 895 | 16 |
| Long-term assets: | Total long-term assets | 49,300 | 23,685 |
| Long-term assets: | Total assets | 507,930 | 638,499 |
| Current liabilities: | Accounts payable | 19,295 | 15,700 |
| Current liabilities: | Accrued expenses and other current liabilities | 21,979 | 26,564 |
| Current liabilities: | Current portion of deferred revenue | 9,111 | 44,440 |
| Current liabilities: | Current portion of operating lease liability | 4,375 | 8,361 |
| Current liabilities: | Total current liabilities | 54,760 | 95,065 |
| Long-term liabilities: | Deferred revenue, net of current portion | 12,338 | 7,798 |
| Long-term liabilities: | Operating lease liability, net of current portion | 38,896 | 9,405 |
| Long-term liabilities: | Total long-term liabilities | 51,234 | 17,203 |
| Long-term liabilities: | Total liabilities | 105,994 | 112,268 |
| Long-term liabilities: | Series A preferred stock, no par value; nil and 3,901,348 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | $— | 7,874 |
| Stockholders’ equity: | Preferred stock, $0.001 par value per share; 30,000,000 shares authorized; nil shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | $— | $— |
| Stockholders’ equity: | Common stock, $0.001 par value per share; 500,000,000 shares authorized; 197,213,583 and nil shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 197 | 1,616,478 |
| Stockholders’ equity: | Additional paid-in capital | 1,885,894 | 228,365 |
| Stockholders’ equity: | Accumulated other comprehensive loss | -565 | -250 |
| Stockholders’ equity: | Accumulated deficit | -1,483,590 | -1,326,236 |
| Stockholders’ equity: | Total stockholders’ equity | 401,936 | 518,357 |
| Stockholders’ equity: | Total liabilities, Series A preferred stock, and stockholders’ equity | 507,930 | 638,499 |
